Alerta

BLOOD GLUCOSE LEVEL MEASUREMENT DEVICE AND BLOOD GLUCOSE LEVEL MEASUREMENT METHOD

Resumen de: WO2025239063A1

This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects light that has been output by the light output unit and passed through a living body; a temporal phase difference calculation unit that, on the basis of the detection result of the light detection unit, calculates the temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration of the blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration of the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; a level of similarity estimation unit that estimates the level of waveform similarity between the oxygenated hemoglobin waveform and the deoxygenated hemoglobin waveform; and a reliability estimation unit that estimates the reliability of the calculated blood glucose level. The reliability estimation unit estimates that the reliability becomes smaller as the level of waveform similarity becomes smaller.

NON-INVASIVE MONITORING SYSTEM

Resumen de: AU2025259892A1

(57) Abstract: A wearable device for non-invasive monitoring of the presence, amount, and/or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes. (57) Abstract: A wearable device for non-invasive monitoring of the presence, amount, and/or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes. ct c t

System, device and method of dynamic glucose profile response to physiological parameters

Resumen de: AU2025259998A1

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. ov o v

SYSTEMS AND METHODS FOR CONTINUOUS GLUCOSE MONITORING OUTCOME PREDICTIONS

Resumen de: AU2024252061A1

Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: US2025352093A1

The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: US2025352095A1

The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.

CLOSED-LOOP BLOOD GLUCOSE CONTROL SYSTEMS AND METHODS

Resumen de: US2025352726A1

A control device (30) for determining a recommendation value of a control parameter of an insulin infusion device (20).

MEDICATION DELIVERY DEVICES, SYSTEMS AND METHODS

Resumen de: US2025352731A1

Medication delivery methods, devices and systems are provided, the medication delivery device includes user interface elements, control circuitry, and a memory. The method includes receiving analyte measurement data of a user, presenting information related to the analyte measurement data to the user, and determining an intended dose of medication based on at least one of the analyte measurement data, optionally, therapeutic relevant conditions, therapy parameters, or a calculated insulin-on-board (IOB) value. When the user is queried to indicate that the user is ready for the delivery without presenting the intended dose on any of the one or more user interface elements of the medication delivery device, the intended dose is automatically delivered after receiving the user's indication.

SENSOR OR CANULA INSERTION PRE-TREATEMENT APPARATUS, METHOD AND SYSTEM

Resumen de: US2025352737A1

A device and product to prepare and numb the skin of a user prior to the insertion of a sensor or canula under the skin. The invention is an applicator and one or more products dispensed thereby or disposed or positioned thereon, the applicator operable to apply a first product and in some cases, a second product, to the skin. The applicator is further operable to dry the skin so as to allow an adhesive backing of a device to be attached to the skin. Preferably, the invention is used to prepare and numb the skin prior to receiving a sensor from a continuous glucose monitor (CGM) or a canula from a insulin pump.

NEUROMODULATION TO TARGET GLUCOSE TRANSPORTER AND/OR INCRETIN PATHWAYS

Resumen de: US2025352127A1

The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.

HOUSING FOR AN INTEGRATED GLUCOSE MONITORING SYSTEM

Resumen de: US2025352094A1

An integrated glucose monitoring system comprising a glucometer and mobile device housed in a housing. The glucometer includes a measurement component to receive a blood glucose test strip containing a sample of blood of an individual, and a port to transmit the blood glucose measurement to a mobile device. The mobile device communicatively and physically coupled to the glucometer. The mobile device includes a port configured to couple with the glucometer, a communication component to receive the blood glucose measurement from glucometer, a power management component to transmit power to the glucometer, and another port to receive power from a power source to power the mobile device. The housing is to house the glucometer and the mobile device to form a single solitary glucose monitoring system.

MODELING TARGETS OF CONTINUOUS GLUCOSE MONITORING METRICS FOR GLYCEMIC CONTROL

Resumen de: US2025352092A1

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

COMPOSITIONS AND METHODS FOR TREATING POSTURAL TACHYCARDIA SYNDROME

Resumen de: US2025353905A1

The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS). In some embodiments, the POTS is associated with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome (HSD/hEDS). In various embodiments, the invention relates to administering a composition comprising an effective amount of a molecular antagonist of Glucose-dependent Insulinotropic Polpeptide (GIP) to a patient in need thereof. In various embodiments, the molecular antagonist can be provided in a form for convenient self-administration upon the onset of symptoms or to prevent or reduce postprandial POTS symptoms, or in other embodiments, is administered at a set frequency.

Apparatus for Optimizing A Patient's Insulin Dosage Regimen

Resumen de: US2025356983A1

An apparatus for optimizing a patient's insulin dosage regimen over time, comprising: at least a first computer-readable memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; a processor operatively connected to the at least first computer-readable memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen in order to maintain the patient's future blood-glucose-level measurements within a predefined range; and a display operative to display information corresponding to at least the patient's present insulin dosage regimen.

MEDICAL DEVICE DATA PROCESSING AND COMMUNICATION METHODS AND SYSTEMS

Resumen de: EP4649888A2

Methods and devices to monitor an analyte in body fluid are provided. Embodiments include continuous or discrete acquisition of analyte related data from a transcutaneously positioned in vivo analyte sensor automatically or upon request from a user. The detection and/or monitoring of glucose levels or other analytes, such as lactate, oxygen, AIC, or the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes.

MODELING TARGETS OF CONTINUOUS GLUCOSE MONITORING METRICS FOR GLYCEMIC CONTROL

Resumen de: EP4651146A1

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

System and method for non-invasive blood glucose monitoring

Nº publicación: US12471808B1 18/11/2025

Solicitante:

UNIV SOUTH FLORIDA [US]
University of South Florida

Resumen de: US12471808B1

A system and method for continuous glucose monitoring (CGM) of blood in a blood vessel of a patient using a non-invasive sensor composed of a patch antenna operating in the Industrial, Scientific and Medical (ISM) Radio band (5.725 GHz-5.875 GHz). The device determines the blood glucose concentration of the blood in the blood vessel based on the measured shift of the resonant frequency of the non-invasive antenna patch sensor. A radio frequency (RF) synthesizer is used to drive the patch antenna with a fraction of its output coupled to both the antenna and receiver through a directional coupler. In this approach both the transmitted (FWD) and received (REV) power are processed, by demodulating logarithmic amplifiers, which convert the RF signals to corresponding voltages for downstream processing. The resulting voltages are then fed into a microcontroller and the measured shift in resonant frequency is converted to a real-time glucose concentration.